RT Journal Article
SR Electronic
T1 Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.02.22275932
DO 10.1101/2022.06.02.22275932
A1 Rass, Verena
A1 Tymoszuk, Piotr
A1 Sahanic, Sabina
A1 Heim, Beatrice
A1 Ausserhofer, Dietmar
A1 Lindner, Anna
A1 Kofler, Mario
A1 Mahlknecht, Philipp
A1 Boehm, Anna
A1 Hüfner, Katharina
A1 Pizzini, Alex
A1 Sonnweber, Thomas
A1 Kurz, Katharina
A1 Pfeifer, Bernhard
A1 Kiechl, Stefan
A1 Peball, Marina
A1 Kindl, Philipp
A1 Putnina, Lauma
A1 Fava, Elena
A1 Djamshidian, Atbin
A1 Huber, Andreas
A1 Wiedermann, Christian J.
A1 Sperner-Unterweger, Barbara
A1 Wöll, Ewald
A1 Beer, Ronny
A1 Schiefecker, Alois Josef
A1 Bellmann-Weiler, Rosa
A1 Bachler, Herbert
A1 Tancevski, Ivan
A1 Pfausler, Bettina
A1 Piccoliori, Giuliano
A1 Seppi, Klaus
A1 Weiss, Günter
A1 Löffler-Ragg, Judith
A1 Helbok, Raimund
YR 2022
UL http://medrxiv.org/content/early/2022/06/03/2022.06.02.22275932.abstract
AB Background Olfactory dysfunction (OD) often accompanies acute coronavirus disease 2019 (COVID-19) and its sequelae. Herein, we investigated OD during COVID-19 recovery in the context of other symptoms, quality of life, physical and mental health.Methods Symptom recovery patterns were analyzed in a bi-national, ambulatory COVID-19 survey (n = 906, ≥ 90 days follow-up) and a multi-center observational cross-sectional cohort of ambulatory and hospitalized individuals (n = 108, 360 days follow-up) with multi-dimensional scaling, association rule mining and partitioning around medoids clustering.Results Both in the ambulatory collective (72%, n = 655/906) and the cross-sectional ambulatory and hospitalized cohort (41%, n = 44/108) self-reported OD was frequent during acute COVID-19, displayed a slow recovery pace (ambulatory: 28 days, cross-sectional: 90 days median recovery time) and commonly co-occurred with taste disorders. In the ambulatory collective, a predominantly young, female, comorbidity-free group of convalescents with persistent OD and taste disorder (>90 days) was identified. This post-acute smell and taste disorder phenotype was characterized by a low frequency of other leading post-acute symptoms including fatigue, respiratory and neurocognitive complaints. Despite a protracted smell and taste dysfunction, this subset had high ratings of physical performance, mental health, and quality of life.Conclusion Our results underline the clinical heterogeneity of post-acute COVID-19 sequelae calling for tailored management strategies. The persistent smell and taste disorder phenotype may represent a distinct COVID-19 recovery pathway characterized by a good recovery of other COVID-19 related symptoms.Study registration ClinicalTrials.gov: NCT04661462 (ambulatory collective), NCT04416100 (cross-sectional cohort).Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at ww.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; PT owns a data science enterprise, Data Analytics as a Service Tirol, and have received an honorarium for statistical data analysis and scientific writing of the manuscript; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis paper was supported by the following grants of Land Tirol GZ 71934 to Judith Loeffler-Ragg and of Boehringer Ingelheim IIS 1199-0424 to Ivan Tancevski.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were reviewed and approved by the institutional review boards of the Medical University of Innsbruck (HACT AT, approval number: 1257/2020, CovILD: 1103/2020) and of the Autonomous Province of Bolzano - South Tyrol (HACT IT, approval number: 0150701).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data files will be made available upon request. https://github.com/PiotrTymoszuk/hyposmia_analsis_pipeline